Literature DB >> 20093331

Is it the patient or the physician who cannot tolerate anemia? A prospective analysis in 1854 non-transfused coronary artery surgery patients.

Sahin Senay1, Fevzi Toraman, Hasan Karabulut, Cem Alhan.   

Abstract

BACKGROUND AND
OBJECTIVE: Low hematocrit level and transfusion may coexist during cardiopulmonary bypass and the actual impact of one on the outcome parameters may be counfounded or masked by the other. This study aims to determine the impact of the lowest hematocrit level during cardiopulmonary bypass on outcome parameters in non-transfused patients.
METHODS: Two thousand six hundred and thirty-two consecutive patients who underwent isolated coronary artery bypass graft (CABG) surgery with cardiopulmonary bypass were evaluated prospectively:1854 (70.4%) patients who did not receive any red blood cells during hospital stay were included in the study. Perioperative data and outcome parameters were recorded. Outcomes were evaluated in 2 groups according to the lowest level of hematocrit (>21%: high hematocrit group, n = 1680, (91.6%) and < or = 21%: low hematocrit group, n = 174, (9.4%)) during cardiopulmonary bypass.
RESULTS: Overall mean lowest hematocrit level of patients was 27.7 + or - 4.4% (19.7 + or - 1.9% in the low hematocrit group, 28.5 + or - 4.1% in the high hematocrit group). The comparison of outcome parameters regarding the time on ventilator, duration of intensive care unit stay, intensive care unit re-admission, hospital re-admission, reoperation for bleeding or tamponade, low cardiac output, postoperative atrial fibrillation, stroke, creatinine level at hospital discharge, new onset renal failure, mediastinitis, pulmonary complication and mortality rates were similar in both groups.
CONCLUSIONS: Our findings suggest that a lowest hematocrit level of < or = 21% during cardiopulmonary bypass has no adverse impact on outcome after isolated coronary surgery in non-transfused patients.

Entities:  

Mesh:

Year:  2009        PMID: 20093331     DOI: 10.1177/0267659109358118

Source DB:  PubMed          Journal:  Perfusion        ISSN: 0267-6591            Impact factor:   1.972


  6 in total

Review 1.  Building a patient blood management program in a large-volume tertiary hospital setting: Problems and solutions.

Authors:  Serdar Günaydın; Donat R Spahn; Kanat Özışık; Aslı Demir; Göktan Aşkın; Doğan Emre Sert; Hale Bozkurt; Ali Şampiyon; Dilek Kazancı; Arnel Boke Kılıçlı; Şeref Alp Küçüker; Ümit Kervan; Mehmet Ali Özatik
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2020-07-28       Impact factor: 0.332

Review 2.  Therapeutic options to minimize allogeneic blood transfusions and their adverse effects in cardiac surgery: a systematic review.

Authors:  Antônio Alceu dos Santos; José Pedro da Silva; Luciana da Fonseca da Silva; Alexandre Gonçalves de Sousa; Raquel Ferrari Piotto; José Francisco Baumgratz
Journal:  Rev Bras Cir Cardiovasc       Date:  2014 Oct-Dec

3.  The effect of postoperative positive end-expiratory pressure on postoperative bleeding after off-pump coronary artery bypass grafting.

Authors:  Yahya Yildiz; Ece Salihoglu; Sezai Celik; Murat Ugurlucan; Ilker Murat Caglar; Fatma Nihan Turhan-Caglar; Omer Isik
Journal:  Arch Med Sci       Date:  2014-10-23       Impact factor: 3.318

4.  Development of an open-heart intraoperative risk scoring model for predicting a prolonged intensive care unit stay.

Authors:  Sirirat Tribuddharat; Thepakorn Sathitkarnmanee; Kriangsak Ngamsangsirisup; Somrat Charuluxananan; Cameron P Hurst; Suparit Silarat; Ganjana Lertmemongkolchai
Journal:  Biomed Res Int       Date:  2014-04-10       Impact factor: 3.411

5.  Mortality risk is dose-dependent on the number of packed red blood cell transfused after coronary artery bypass graft.

Authors:  Antônio Alceu dos Santos; Alexandre Gonçalves Sousa; Raquel Ferrari Piotto; Juan Carlos Montano Pedroso
Journal:  Rev Bras Cir Cardiovasc       Date:  2013 Oct-Dec

6.  Therapeutic Plasma Exchange Ameliorates Incompatible Crossmatches.

Authors:  Mehmet Özen; Sinan Erkul; Gülen Sezer Alptekin Erkul; Özlem Genç; Engin Akgül; Ahmet Hakan Vural
Journal:  Turk J Haematol       Date:  2016-10-18       Impact factor: 1.831

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.